Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

4.185 +0.025 (+0.60%)
Streaming Delayed Price Updated: 3:25 PM EDT, Sep 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ARS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
ARS Pharma (SPRY) Q2 2026 Earnings Call Transcript ↗
Neffy market share doubled as prescriber count tripled year over year. 
Via The Motley Fool
Topics Earnings
News headline image
ARS Pharmaceuticals Q2 Earnings Call Highlights ↗
ARS Pharmaceuticals (NASDAQ:SPRY) outlined a revised commercial and spending strategy during its second-quarter 2026 earnings call, with new President and CEO Donn Casale emphasizing provider-focused... 
Via MarketBeat
Topics Earnings
News headline image
ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript ↗
ARS Pharmaceuticals (NASDAQ:SPRY) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide... 
Via Benzinga
Topics Earnings
Which stocks are moving before the opening bell on Thursday? ↗
Via Chartmill
ARS Pharmaceuticals (NASDAQ:SPRY) Reports Revenue Growth in Q1 2026, Net Loss Widens on Commercial Investment ↗
Via Chartmill
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
Earnings Outlook For ARS Pharmaceuticals ↗
 
Via Benzinga
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
ARS Pharma (SPRY) Q1 2026 Earnings Transcript ↗
ARS Pharma (SPRY) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
ARS Pharma (SPRY) Q4 2025 Earnings Transcript ↗
ARS Pharma (SPRY) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Earnings Outlook For ARS Pharmaceuticals ↗
 
Via Benzinga
News headline image
ARS Pharmaceuticals's Earnings: A Preview ↗
 
Via Benzinga
News headline image
ARS Pharmaceuticals Q1 Earnings Call Highlights ↗
ARS Pharmaceuticals (NASDAQ:SPRY) reported first-quarter 2026 revenue of $22.7 million as executives said the company is working to expand access, reduce prescribing friction and build momentum for... 
Via MarketBeat
Topics Earnings
News headline image
ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) to release first quarter earnings on May 15 before opening bell. Analysts expect a loss of 54 cents per share. 
Via Benzinga
News headline image
Got $300? 2 Biotech Stocks to Buy and Hold Forever ↗
These two biotechs only have one marketable therapy each, but both have blockbuster potential. 
Via The Motley Fool
News headline image
ARS Pharma SPRY Q3 2025 Earnings Call Transcript ↗
ARS Pharma SPRY Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
ARS Pharmaceuticals Inc (NASDAQ:SPRY) Tops Q3 2025 Revenue Forecasts Amid Wider-Than-Expected Loss ↗
ARS Pharma beats Q3 2025 revenue estimates with strong neffy sales. The company reports a wider loss but shows robust commercial growth and global expansion. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
ARS Pharma Urges FDA To Delay Approval Of Aquestive's Allergic Reaction Treatment ↗
ARS Pharmaceuticals petitioned the FDA to delay approval of Aquestive's epinephrine film, citing safety, dosing, and cardiovascular concerns. 
Via Benzinga
News headline image
ARS Pharma Sales Jump 3,040% in Q2 ↗
Via The Motley Fool
News headline image
ARS Pharmaceuticals Inc (NASDAQ:SPRY) Reports Mixed Q2 2025 Earnings with Revenue Beat but Investor Caution Persists ↗
ARS Pharma Q2 2025 results: $15.7M revenue beats estimates, but stock dips amid high SG&A costs. neffy gains traction with 93% U.S. coverage and global expansion underway. 
Via Chartmill
News headline image
Earnings Scheduled For August 13, 2025 ↗
 
Via Benzinga
News headline image
Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs ↗
Jim Cramer recommends Union Pacific but is "getting tired of the orphan drug model." Here's what the "Mad Money" host said. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are gapping on Thursday? ↗
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why. ↗
The company is known for its first-of-a-kind drug, a nasal treatment for emergency allergic reactions. 
Via Investor's Business Daily
News headline image
Earnings Scheduled For May 14, 2025 ↗
 
Via Benzinga
News headline image
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 20, 2025 ↗
 
Via Benzinga
News headline image
FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment ↗
FDA approves ARS Pharma's Neffy 1 mg, the first nasal epinephrine spray for children with severe allergies, offering a needle-free alternative to autoinjectors. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.